-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron to Present Ordspono Trial Results in Relapsed or Refractory Marginal Zone Lymphoma at ASH

PUBT·11/19/2026 12:07:08
Listen to the news
Regeneron to Present Ordspono Trial Results in Relapsed or Refractory Marginal Zone Lymphoma at ASH
  • Regeneron will present new hematology data across 14 abstracts at ASH, December 12-15, 2026, in New Orleans.
  • Ordspono’s potentially registration-supporting ELM-2 primary analysis in relapsed or refractory marginal zone lymphoma will be presented December 14.
  • Lynozyfic’s longer-term LINKER-AL2 results in relapsed or refractory systemic light chain amyloidosis will be presented December 12, building on previously reported efficacy.
  • A separate analysis will compare cemdisiran-pozelimab with ravulizumab in paroxysmal nocturnal hemoglobinuria, assessing disease control and transfusion avoidance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190700PRIMZONEFULLFEED9880795) on November 19, 2026, and is solely responsible for the information contained therein.